TrialSignal transduction and targeted therapy2024

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.

Yanni Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.